Abstract
Pharmacogenomics is an evolving research discipline within ophthalmology. An early application appears to involve open-angle glaucoma, a common cause of worldwide preventable blindness. Primary open-angle glaucoma is primarily treated with medications, and the two most common classes of drugs are β-adrenergic receptor antagonists and prostaglandin analogs. One small clinical trial has documented a pharmacogenomic relationship between polymorphisms in the β1-adrenergic receptor with the selective β 1-antagonist betaxolol. A second small clinical trial has documented a pharmacogenomic relationship between polymorphisms in the prostaglandin F2α receptor and the prostaglandin analog latanoprost. A small pilot study has not found any significant pharmacogenomic relationship between polymorphisms in the glucocorticoid receptor and intraocular pressure elevation following treatment with intravitreal triamcinolone acetonide. Pharmacogenomics may explain some of the well-documented variability in response to common glaucoma medications.
| Original language | English |
|---|---|
| Pages (from-to) | 121-125 |
| Number of pages | 5 |
| Journal | Current Pharmacogenomics and Personalized Medicine |
| Volume | 6 |
| Issue number | 2 |
| State | Published - Dec 1 2008 |
Fingerprint
ASJC Scopus subject areas
- Genetics
- Molecular Medicine
- Pharmacology
- Molecular Biology
- Genetics(clinical)
Cite this
Pharmacogenomics of open-angle glaucoma. / Schwartz, Stephen; Ayala Haedo, Juan; Kishor, Krishna; Fini, M. Elizabeth.
In: Current Pharmacogenomics and Personalized Medicine, Vol. 6, No. 2, 01.12.2008, p. 121-125.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Pharmacogenomics of open-angle glaucoma
AU - Schwartz, Stephen
AU - Ayala Haedo, Juan
AU - Kishor, Krishna
AU - Fini, M. Elizabeth
PY - 2008/12/1
Y1 - 2008/12/1
N2 - Pharmacogenomics is an evolving research discipline within ophthalmology. An early application appears to involve open-angle glaucoma, a common cause of worldwide preventable blindness. Primary open-angle glaucoma is primarily treated with medications, and the two most common classes of drugs are β-adrenergic receptor antagonists and prostaglandin analogs. One small clinical trial has documented a pharmacogenomic relationship between polymorphisms in the β1-adrenergic receptor with the selective β 1-antagonist betaxolol. A second small clinical trial has documented a pharmacogenomic relationship between polymorphisms in the prostaglandin F2α receptor and the prostaglandin analog latanoprost. A small pilot study has not found any significant pharmacogenomic relationship between polymorphisms in the glucocorticoid receptor and intraocular pressure elevation following treatment with intravitreal triamcinolone acetonide. Pharmacogenomics may explain some of the well-documented variability in response to common glaucoma medications.
AB - Pharmacogenomics is an evolving research discipline within ophthalmology. An early application appears to involve open-angle glaucoma, a common cause of worldwide preventable blindness. Primary open-angle glaucoma is primarily treated with medications, and the two most common classes of drugs are β-adrenergic receptor antagonists and prostaglandin analogs. One small clinical trial has documented a pharmacogenomic relationship between polymorphisms in the β1-adrenergic receptor with the selective β 1-antagonist betaxolol. A second small clinical trial has documented a pharmacogenomic relationship between polymorphisms in the prostaglandin F2α receptor and the prostaglandin analog latanoprost. A small pilot study has not found any significant pharmacogenomic relationship between polymorphisms in the glucocorticoid receptor and intraocular pressure elevation following treatment with intravitreal triamcinolone acetonide. Pharmacogenomics may explain some of the well-documented variability in response to common glaucoma medications.
UR - http://www.scopus.com/inward/record.url?scp=56249088466&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=56249088466&partnerID=8YFLogxK
M3 - Article
AN - SCOPUS:56249088466
VL - 6
SP - 121
EP - 125
JO - Current Pharmacogenomics and Personalized Medicine
JF - Current Pharmacogenomics and Personalized Medicine
SN - 1875-6921
IS - 2
ER -